Allianz减少了在2025年问题2中的Teva股份;公司比收入估计数低,但损失了收入,维持了全年指导。 Allianz reduced its Teva stake in Q2 2025; company beat earnings estimates but missed revenue, maintaining full-year guidance.

Allianz资产管理公司在Teva制药公司的股份在2025年Q2减少了34 916股,现在持有644 076股,价值1 080万美元。 Allianz Asset Management reduced its stake in Teva Pharmaceutical by 34,916 shares in Q2 2025, now holding 644,076 shares valued at $10.8 million. Yousif资本管理增加了2 830股股份,使其股份增加到58 816股。 Yousif Capital Management added 2,830 shares, raising its stake to 58,816. Teva报告说,Q2收入为每股0.66美元,尽管收入不足,但估计是亏损。 Teva reported Q2 earnings of $0.66 per share, beating estimates, though revenue fell short. 该公司将2025财政年度EPS指导维持在2.50美元-2.60美元,分析师预测为2.50美元。 The company maintained FY 2025 EPS guidance at $2.50–$2.60, with analysts forecasting $2.50. 股票有一个一致的“Buy”评级和25.57美元平均价格目标。 The stock has a consensus "Buy" rating and a $25.57 average price target. 混合分析师的情绪依然存在,有些升级为“强购”,而另一些则保持“销售”评级。 Mixed analyst sentiment persists, with some upgrading to "strong-buy" and others maintaining "sell" ratings.